Skip to main content
. Author manuscript; available in PMC: 2020 Aug 15.
Published in final edited form as: Cancer Res. 2019 Dec 16;80(4):771–783. doi: 10.1158/0008-5472.CAN-19-1145

Figure 4.

Figure 4.

Both mITGB4-DC vaccination and mITGB4 BiAb-armed TDLN T cell transfer specifically target ITGB4. A, B: Confirmation of ITGB4 knockout in 4T1-ITGB4KO cells and lack of expression of ITGB4 in CT26 cells via western blot (A) and flow cytometry (B). C, D: ITGB4-targeted cancer immunotherapies specifically target ITGB4 in vivo. mITGB4-DC (C) and TDLN T-mITGB4 BiAb (D) significantly inhibited the tumor growth of 4T1 cells, but not 4T1-ITGB4KO or ITGB4-negative CT26 tumors. Experimental groups included 4T1, 4T1-ITGB4KO or CT26 tumor-bearing mice treated with PBS vs. mITGB4-DC vaccine in minimal tumor model (C) or treated with PBS vs. TDLN T-mITGB4 BiAb in established tumor model (D). E: CD3+ T cells isolated from the spleens of Balb/c mice treated with mITGB4-DC vaccine killed ITGB4-expressing 4T1 cells specifically in vitro. F: TDLN T-mITGB4 BiAb mediated significant greater cytotoxicity to ITGB4-expressing 4T1 cells than to 4T1-ITGB4KO cells or ITGB4-negative CT26 cells in vitro.